Capula Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,300
Closed -$315K 1091
2025
Q4
$315K Sell
3,300
-19,700
-86% -$1.93M ﹤0.01% 481
2025
Q3
$2.25M Buy
23,000
+19,600
+576% +$2.03M 0.01% 222
2025
Q2
$365K Sell
3,400
-900
-21% -$91.1K ﹤0.01% 270
2025
Q1
$434K Buy
+4,300
New +$433K ﹤0.01% 325
2023
Q2
Sell
-136,800
Closed -$6.84M 466
2023
Q1
$6.84M Sell
136,800
-3,200
-2% -$151K 0.08% 198
2022
Q4
$6.48M Buy
+140,000
New +$6.06M 0.09% 226
2021
Q1
Sell
-39,800
Closed -$1.43M 493
2020
Q4
$1.43M Buy
+39,800
New +$1.43M 0.07% 192
2020
Q3
Sell
-30,000
Closed -$1.05M 160
2020
Q2
$1.05M Buy
+30,000
New +$1.08M 0.04% 246
2020
Q1
Sell
-44,200
Closed -$2M 366
2019
Q4
$2M Sell
44,200
-69,400
-61% -$2.9M 0.04% 259
2019
Q3
$4.62M Buy
+113,600
New +$4.81M 0.1% 171

Other funds holding BSX

Capula Management's BSX Position: Q2 2026 in Review

Capula Management opened a new position in Boston Scientific (BSX) in Q2 2026: 15,222 shares worth $650K. The stake represents ﹤0.01% of the portfolio and ranks #348 among its holdings. This is a return to the name: Capula Management previously reported a position in BSX as recently as Q4 2025.

Capula Management first reported a position in BSX in Q3 2019 and has held it in 9 quarters since. The position peaked at $821K in Q3 2019. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Capula Management held 15,222 shares of Boston Scientific worth $650K as of Q2 2026.
  • Boston Scientific was a new Capula Management position in Q2 2026.
  • Boston Scientific made up ﹤0.01% of Capula Management's portfolio in Q2 2026, its #348 holding.
  • Capula Management first reported a position in Boston Scientific in Q3 2019 and has held it in 9 quarters since.
  • Capula Management's Boston Scientific position peaked at $821K in Q3 2019.
  • 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.